KimMargolinMD
Oncology • Santa Monica, CAHematologic Oncology, Melanoma
Professor of Medicine, Stanford University Division of Oncology
Dr. Margolin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2121 Santa Monica Blvd
Santa Monica, CA 90404Phone+1 310-829-8317Fax+1 310-315-6143
Education & Training
City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1985- City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1983
Yale-New Haven Medical CenterResidency, Internal Medicine, 1979 - 1982
Stanford University School of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 1982 - 2025
WA State Medical License 2008 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
- Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Start of enrollment: 2019 Nov 27
Publications & Presentations
PubMed
- 582 citationsRandomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffery R. Weiss
Journal of Clinical Oncology. 2005-01-01 - 883 citationsPD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul Nghiem, Shailender Bhatia, Evan J. Lipson, Ragini R. Kudchadkar, Natalie J. Miller
The New England Journal of Medicine. 2016-04-19 - 34 citationsMelanoma central nervous system metastases: current approaches, challenges, and opportunities.Justine V Cohen, Hussain Tawbi, Kim A Margolin, Ravi Amravadi, Marcus Bosenberg
Pigment Cell & Melanoma Research. 2016-11-01
Journal Articles
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaIgor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Authored Content
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Press Mentions
Oncologists Celebrate the Legacy of Dr. Jeffrey S. Weber, “the Consummate Physician-Scientist”August 26th, 2024- What Is the Latest Research on the Form of Cancer Jimmy Carter Has?March 3rd, 2023
- Immunotherapy: Researchers Identify Ways to Help Predict Outcomes for Cancer TreatmentFebruary 14th, 2023
- Join now to see all
Grant Support
- Academic Industry AwardMelanoma Research Alliance, Altor Bioscience2012–2014
Other Languages
- Spanish, French, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
